The objective of the study was to assess the associations of dyslipidaemia, combined oral contraceptive (COC) use and their interaction on the risk of hypertension in Chinese women. In a case-control study, we evaluated 665 hypertensive women and 665 normotensive women matched on region and age in China. Hypertensive women had a higher prevalence of dyslipidaemia and higher levels of total cholesterol, triglyceride, low-density lipoprotein-cholesterol and lipoprotein a than normotensive ones (Po0.05). The risk of hypertension gradually increased with the increasing cumulative time of COC use in women (P ¼ 0.0043), especially significantly increased among those with cumulative time of COC use15-20 and X20 years (adjusted odds ratio (OR) ¼ 1.46, 95% confidence interval (CI): 1.00-2.15; OR ¼ 1.49, 95% CI: 1.06-2.11), but gradually decreased from stopping use of COC (Po0.0001). The multiplicative interaction between dyslipidaemia and accumulative time of COC use X15 years, dyslipidaemia and family history of hypertension, or family history of hypertension and accumulative time of COC use X15 years was confirmed and the interaction analyses showed that they can significantly increased the risk of hypertension (adjusted OR ¼ 2.82, 95% CI: 1.59-3.27; OR ¼ 4.33, 95% CI: 3.10-6.06; OR ¼ 4.56, 95% CI: 3.07-6.77). It is concluded that dyslipidaemia, accumulative time of COC use X15 years and their interaction increased the risk of hypertension.
Introduction
Dyslipidaemia is a common metabolism abnormality in hypertensive person and a strong predictor of cardiovascular disease. 1, 2 Dyslipidaemia and hypertension were observed to be combined and influenced with each other to increase the risk of cardiovascular diseases. 3 In China, results from the investigation on national inhabitant nutrition and health in 2002 showed a prevalence rate of 18.8% or an estimated of 160 million adults had hypertension and 50% of them combined with dyslipidaemia. 4 Several studies have provided strong evidence for the important function of dyslipidaemia on the risk of hypertension. [5] [6] [7] [8] Cross-sectional studies have suggested a link between abnormal lipids and hypertension. 5, 7 A few studies have prospectively examined the relationship between plasma lipids and the future development of hypertension, finding that there is an association between plasma lipids and development of hypertension. 6, 8 Moreover, family study showed that there was a clustering phenomenon of dyslipidaemia in hypertensive families. 9 Oral contraception remains as one of the effective contraceptive methods most commonly used worldwide. At present, it is estimated that 150 million women around the world use combined oral contraceptive (COC). 10 In the United States, approximately 11.6 million or 19% of women are using COC. 10 Although the prevalence rate of COC use in China is only 1.5%, the absolute number of COC user is larger because of enormous general population. 11, 12 As it was introduced in the 1960s, COC has been implicated in increasing cardiovascular risk following use. 13, 14 Hypertension is one of the most common side effects and has been acknowledged as a relative contraindication for COC use. 14 The majority of studies documenting the association between hypertension and COC use involved firstgeneration COC (50 mg or more of oestrogen). 15 Up to 5% women using first-generation COC may develop hypertension. 16 Although it was suggested that the incidence of hypertension would be lower with lower oestrogen doses, significant rise in blood pressure has also been verified. 17, 18 In addition, it was reported that COC users with hypertension family history were more likely to develop hypertension. 19 A study from Greenlund et al. 20 has shown that there was an association between plasma lipids and COC use.
There is increasing evidence demonstrating that interaction between risk factors has an important function in the studies of complex trait diseases. Hypertension is also considered as a complex trait disease resulting from the interaction between genetic and environmental factors. It is well known that dyslipidaemia or COC use was strongly related to hypertension. However, few data to date were available with regard to the interaction between dyslipidaemia and COC use on the risk of hypertension. Accordingly, the aim of this study was to investigate dyslipidaemia, COC use and their interaction on the risk of hypertension in a case-control design in Chinese women and to provide suggestions for guiding safe use of COC and studying etiological factor of women with hypertension.
Subjects and methods

Subjects
Rudong and Taicang counties were the pilot regions of COC use, and the percentage of COC use was the highest in China. 12 In 2003, all of the women resided in the two counties were investigated for the intervention study of hypertension. On the basis of this, a case-control study was carried out from April to May in 2004 to investigate dyslipidaemia, COC use and their interaction on the risk of hypertension in Chinese women. A total of 1330 female subjects were recruited, of whom 665 hypertensive women were enrolled according to the criteria from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7): systolic blood pressure (SBP) X140 mm Hg and/or diastolic blood pressure (DBP) X90 mm Hg; previously diagnosed as hypertension and still with antihypertensive treatment. 21 Then 665 normotensives were matched on region and age (±3 years), according to the criteria of SBP o140 mm Hg and DBP o90 mm Hg, and they never been diagnosed as hypertension or other cardiovascular diseases. The study was approved by the Human Subjects Committees of Jiangsu Institute of Planned Parenthood Research, Nanjing, China. Written informed consent was obtained from each participant.
Methods
This case-control study was carried out using faceto-face interviews by trained interviewers. Information on demographics, medical history, family history of hypertension, COC use, weekly alcohol intake and the clinical examination was collected with standardized questionnaires. Blood pressure, height and body weight were measured. Body mass index (BMI) was calculated as weight divided by height (kilograms divided by square metres). Overweight was defined as BMI X24 kg m À2 . 22 Individuals who consumed alcohol more than once a week were categorized as alcohol drinkers.
COC exposure. Contraceptives are provided for free by the national family planning system in China. Women who are willing to use COC for contraception must get COC from the local family planning clinics monthly. The records of the type and cumulative time of COC use have been maintained by the local family planning clinics. Thus, the cumulative time of COC use could be acquired accurately. In this study, less than 3 months of the cumulative time of COC use was considered as a nonuser. More than 3 months was defined as a COC user.
Blood measurement. Blood pressure was measured by trained doctors using desktop mercury sphygmomanometer, on the left arm in precordial level after at least 10 min of rest and with the subjects in sitting position. SBP was defined by the first Korotkoff sound and DBP by the fifth sound. Two measurements were done, at least 5 min apart. The average of two blood pressure readings was used for the diagnosis of hypertension.
Lipid and apolipoprotein measurements. Venous blood sample was drawn from an antecubital vein by venipuncture from subjects after 12 h fast. The sample was transferred into tubes containing EDTA. Immediately following, plasma was separated by low-speed centrifugation for 15 min at 3000 r.p.m. and was stored at À20 1C, then the analysis was carried out within 1 week. The levels of total cholesterol (TC), triglyceride (TG) and high-density lipoprotein-cholesterol (HDL-C) were determined by enzymatical methods using commercially available kits (Randox Co. Ltd, UK; Randox Co. Ltd, UK; Daiichi fine chemical Co. Ltd, Japan). Serum apolipoprotein (apo) A1, apo B and lipoprotein a levels were measured by immunoturbidimetric assay (Beijia Reagent Co. Ltd, shanghai, China; Shenfeng Reagent Co. Ltd, shanghai, China). Low-density lipoprotein-cholesterol (LDL-C) was calculated. All determinations were performed on a Hitachi 7150 autoanalyzer (Hitachi Ltd, Tokyo, Japan). Hypercholesterolemia was defined as TC X5.18 mmol l
À1
, high LDL-C as LDL-C X3.37 mmol l
, hypertriglyceridaemia as TG X1.7 mmol l À1 and low HDL-C as HDL-C o1.04 mmol l
. Dyslipidaemia was defined by the presence of one or more than one abnormal serum lipid level. 23, 24 Statistical methods. Differences in demographic characteristics between the cases and controls were Dyslipidaemia, COC use and their interaction on hypertension W Wei et al calculated using Student's t-test (for continuous variables) and w 2 -test (for categorical variables), respectively. Cochran-Artimage approach was used for tendency test. Associations of cumulative time of COC use or stopping of COC use with risk of hypertension were estimated by computing adjusted odds ratios (ORs) and their 95% confidence intervals (CI) from unconditional logistic regression analyses. The risk factors significantly associated with hypertension were selected using stepwise multiple logistic regression models. The multiplicative interactions of dyslipidaemia, COC use and family history of hypertension were evaluated by incorporating interaction terms in the logistic regression model. All of the statistical analyses were conducted using Statistical Analysis System software (v.9.1.3; SAS Institute, Cary, NC, USA). All tests were two-sided and the value of Po0.05 was considered statistically significant.
Results
Demographic characteristics between hypertensive cases and normotensive controls As summarized in Table 1 , there was no statistically significant difference in the region distribution, age structure, educational level, occupation character or the percentages of subjects who consumed alcohol between two groups (P40.05). About 61.50% of the hypertensive cases were COC users, which was no significantly higher than that of the controls (58.65%) (P ¼ 0.2874). The percentages of family history of hypertension, the levels of BMI and the prevalence of dyslipidaemia in hypertensive cases were higher than those normotensive controls (Po0.0001).
Lipid metabolic parameters between hypertensive cases and normotensive controls As shown in Table 2 , the mean levels of TC, TG, LDL-C and lipoprotein a of hypertensive cases were significantly higher than those of normotensive controls (Po0.0001; Po0.0001; Po0.0001; P ¼ 0.0029), whereas no significant difference in the mean levels of HDL-C, apo A1 or apo B was observed between the two groups (P ¼ 0.4567, 0.0991, 0.5891).
Associations between COC use and the risk of hypertension As shown in Tables 3 and 4 , after adjusting for region and age, the risk of hypertension gradually increased with the increasing cumulative time of COC use in women (tendency test P ¼ 0.0043). Compared with nonusers, the risk of hypertension significantly increased among those with cumulative time of COC use15-20 and X20 years (adjusted OR ¼ 1.46, 95% CI: 1.00-2.15; OR ¼ 1.49, 95% CI: 1.06-2.11, respectively). In contrast, the risk of hypertension gradually decreased from stopping use of COC (tendency test Po0.0001).
Associations between COC use and the risk of dyslipidaemia No statistical evidence was observed between COC use and the risk of dyslipidaemia (P40.05) (data not shown).
Logistic regression model of risk factors of hypertension As shown in Table 5 , after region (Rudong, Taicang), accumulative time of COC use (o15 years, X15 years), dyslipidaemia (no, yes) and family history of hypertension (no, yes) were incorporated into the model as binary variables, age and BMI as continuous variable, the stepwise multiple logistic regression model demonstrated that age, family history of hypertension, dyslipidaemia and accumulative time of COC use X15 years were the significant contributors to hypertension. 
Cases (n ¼ 649) 
Discussion
In the present case-control study of hypertension, we evaluated dyslipidaemia, COC use and their interaction on the risk of hypertension. We found that dyslipidaemia and accumulative time of COC use X15 years were the risk factors of hypertension, and their interaction significantly increased the risk of hypertension in Chinese women.
Positive associations between serum lipid levels and hypertension have been well documented. [25] [26] [27] In this study, we also found that the prevalence of dyslipidaemia and levels of TC, TG, LDL-C and lipoprotein a were significantly higher in Chinese hypertensive women than in normotensive ones. However, the results were inconsistent with many epidemiological studies. [4] [5] [6] [7] 28 For example, data in Norway showed that each of TC, HDL-C and TG levels had an independent positive relation with SBP and DBP. 28 In rural Chinese population, the prevalence of HDL-C showed a significant decrease with increased stage of blood pressure. 5 In contrast, no significant difference in the mean levels of HDL-C was observed in our study. This discrepancy may mainly be attributed to the differences in populations, gender, age, region and so on. On the other hand, biological interactions among risk factors may be parts of the explanations of this conflicting result.
Although the biological mechanism for the COC use on the development of hypertension remained to be elucidated, several studies demonstrated that there was an association between COC use and hypertension. 16, 29 For instance, in a large prospective cohort study conducted in American nurses, a doubling in the adjusted relative risk for hypertension was documented in current users of COC. 16 Similarly, a prospective cross-section study found an association between DBP and COC use. 29 In this study, we found that the risk of hypertension increased with increasing cumulative time of COC 16 where those using COC for more than 6 years presented higher risk of developing hypertension (relative risk ¼ 2.1, 95% CI: 1.6-2.7). The study by Lubianca et al. 29 also showed that blood pressure levels were significantly higher in women who had used COC for more than 8 years. All of these results indicated that there was a cumulative effect between COC use and development of hypertension. The rises in blood pressure caused by using COC may occur after a long time. It was suggested that long term using of COC may be the risk factor of hypertension.
Only several cohort studies have focused on the relationship between stopping the use of COC and risk of hypertension, which showed that risk was directly proportional to decreased blood pressure levels of individuals. [30] [31] [32] In the cohort study by Lubianca et al., 30 a reduction of at least 20 mm Hg in SBP or 10 mm Hg in DBP were observed (OR ¼ 0.28, 95% CI: 0.08-0.90) in women who stopped using COC compared with those did not stop using COC. Similarly, in a previous study by Ribstein et al., 31 a decrease in blood pressure was observed in the hypertensive women who were followed up for 6 months after COC withdrawal. The data of our study also indicated a significant decreased risk of hypertension in women who stopped using COC. These results may explain association between COC use and hypertension from another aspect. Stopping the use of COC may be considered as an effective antihypertensive measure in COC users with hypertension.
It was well known that dyslipidaemia or COC use was strongly related to hypertension, 6, 19, 29 which was also documented in our study. In accordance with the previous studies, in our data, multiple logistic regression analysis of the conventional hypertension risk factors also documented that age, BMI, dyslipidaemia, cumulative time of COC use X15 years and family history of hypertension were the most important factors for hypertension in this population. However, to date, few data were available with regard to the interaction between dyslipidaemia and COC use on the risk of hypertension. We were not aware of other studies that had addressed this question through this design, except the previous study by us. 33 A study from Greenlund et al. 20 found that there was an association between plasma lipids and COC use. However, no association was observed between COC use and the risk of dyslipidaemia in our study. It was reported that COC users with hypertension family history were more likely to develop hypertension. 19 In addition, family study showed there was a clustering phenomenon of dyslipidaemia in hypertensive families. 9 Although the biological mechanism involved in the interaction between dyslipidaemia and COC use remained to be elucidated, we found the interactive effects of dyslipidaemia, accumulative time of COC use X15 years and family history of hypertension on the risk of hypertension in Chinese women. It was suggested that interactions of risk factors has an important function in the development of hypertension. It was also considered that studying interactions of risk factors has a more important function than one risk factor in investigating pathogenesis of hypertension.
There are several advantages of this study. First, subjects were selected from Rudong and Taicang countries, which were the earliest regions of COC use and the prevalence of COC use as high as 15% in China. 12 Thus, our study could reflect the association between COC use and hypertension since it was introduced in China. Second, the information bias could be minimized for the information on COC use acquired accurately according to the records of contraceptive use had being maintained by the local family planning clinics. However, several limitations of this study have to be considered. First, our subjects were selected from two regions, inherent selection bias cannot be completely excluded and generalizability of the results to other female populations and settings may be limited. However, we used further statistical adjustment for region and age to minimize potential biases. Second, some interaction analyses on COC use and dyslipidaemia should be interpreted with caution after stratification of the study population, for the sample size may limit the statistical power of our study. Finally, though the available evidence and the biological plausibility reinforced the interpretation, case-control studies have weakness in causal inference. Larger well-designed prospective cohort studies with ethnically diverse populations are needed to confirm our findings.
In conclusion, our data suggested that dyslipidaemia, accumulative time of COC use X15 years, especially their interaction, may have a function in the development of hypertension in Chinese women. However, nowadays, there seems to be less concern with COC use in women with hypertension, because the change in blood pressure is usually described as mild. Some with dyslipidaemia or family history of hypertension even used COC as contraceptive option. Our study suggested that the use of COC in the presence of dyslipidaemia may increase the risk of hypertension. This may also determine the need for pharmacological treatment in hypertensive women whose blood pressure could otherwise have been controlled by nonpharmacological means. Therefore, measurement of lipid should be recommended in women with dyslipidaemia before COC use. 34 COC users should get their blood pressure levels checked regularly during the period when they are using COC and that the onset of hypertension is a reason to stop using COC or consider other forms of contraception. 35 Dyslipidaemia, COC use and their interaction on hypertension W Wei et al
